Astellas Loses Bid for Jury Trial in Remanded Myrbetriq ER Case

Astellas Pharma Inc. can’t add new allegations to its case over copies of its overactive-bladder treatment Myrbetriq ER, a federal judge in Delaware ruled, also denying Astellas’ request for a jury trial after the Federal Circuit revived a patent he’d canceled.

Judge Joseph F. Bataillon rejected Astellas’ motion to supplement its complaint against generic-drug makers including Lupin Ltd. and Zydus Lifesciences Ltd., though he said Astellas could raise its issues in a new lawsuit, in an opinion issued Tuesday in the US District Court for the District of Delaware.

The US Court of Appeals for the Federal Circuit on ...